tbuckley/cabot-search huggingface dataset:
Government must spell out how mental health will achieve parity with physical health, say MPs
Authors: Adrian O’Dowd
Journal: BMJ (2016)

The UK government’s drive to give mental health the same level of resources and attention as physical health is highly unrealistic, say MPs, given the current restraints on the NHS budget in England.

MPs on the parliamentary public accounts committee published a report on 21 September,1 in which they praised the intention to give mental health parity with physical health but raised numerous concerns about how this could be achieved.

They have recommended that the Department of Health and NHS England come up with detailed plans by April next year spelling out the exact costs, how spending should be prioritised, and the extra workforce needed to deliver the policy. The organizations should also develop an effective strategy to integrate health services …
Development and Validation of a Non-Invasive Model for Predicting Fibrosis Resolution One Year after Lifestyle Intervention for Biopsy-Proven Non-Alcoholic Steatohepatitis
Authors: E. Vilar-Gomez, S. Friedman, L. Calzadilla-Bertot, A. Yasells-Garcia, R. Gallego-Duran, J. Ampuero, M. Diago, M. Romero-Gomez
Journal: Journal of Hepatology (2016)
P1061 : The macrophage activation marker SCD163 and the apoptosis marker cytokeratin-18 are both predictors of disease severity in patients with non-alcoholic fatty liver disease
Authors: K. Kazankov, F. Barrera, H.J. Møller, C. Rosso, E. Bugianesi, E. Vanni, S. Esmaili, M. Eslam, D. McLeod, B.M. Bibby, H. Vilstrup, J. George, H. Grønbæk
Journal: Journal of Hepatology (2015)
Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC.
Authors: Yoshihiko Tomita, Sei Naito, Naoto Sassa, Atsushi Takahashi, Tsunenori Kondo, Takuya Koie, Wataru Obara, Yasuyuki Kobayashi, Jun Teishima, Masayuki Takahashi, Hideyasu Matsuyama, Takeshi Ueda, Kenya Yamaguchi, Ken Kishida, Ryoichi Shiroki, Takashi Saika, Shinohara Nobuo, Mototsugu Oya, Hiro-Omi Kanayama
Journal: Journal of Clinical Oncology (2014)

502 Background: Sorafenib (SO), an earlier introduced kinase inhibitor, and sunitinib (SU), a standard first-line treatment drug for metastatic renal cell carcinoma (mRCC), were associated with progression-free survival (PFS) of 5.7 and 11 months (M) in independent clinical trials, respectively. We compared PFS of first-line SU and SO in a multicenter, randomized, open-label, phase III trial. Methods: Patients with untreated, measurable (by RECIST v1.1) clear-cell mRCC stratified according to MSKCC risk criteria, nephrectomy, and institution were randomized in 1:1 to receive SU (50 mg qd 4 wks on-2 wks off) or SO (400 mg bid). The calculated sample size was 59/group for α = 0.05, β = 0.10, and a censoring rate of 15%. Results: Of 124 enrolled patients, from Feb. 2010 to Jul. 2012, from 39 institutions, 120 were evaluable (SU, 57 and SO, 63). Patient baseline characteristics in the SU vs SO groups were as follows: favorable risk, 21% vs 22%; presence of stable brain metastasis, 8.8% vs 1.6% and with nephrectomy, 88% vs 89%. Median PFS (mPFS) was 8.7 and 7.0 M in the SU and SO groups, respectively (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.42–1.08; p= 0.095). mPFS was 31.2 and 6.2 M (HR 0.27, 95%CI 0.08–0.90; p = 0.023) in the favorable risk group, 11.9 and 6.5 M (HR 0.31, 95%CI 0.14–0.69; p = 0.035) in patients with T1 or T2 primary tumors, and 11.6 and 7.0 M (HR 0.41, 95%CI 0.36–0.98; p = 0.038) in those without brain metastasis, in the SU and SO groups, respectively. Objective response rates for SU group was 35.3%; SO was 27.8% (p = 0.407). Overall survival was not reached. The most common adverse events (all grade, all cause) were hand-foot syndrome (SU vs SO, 71% vs 86%), hypothyroidism (70% vs 33%), fatigue (57% vs 40%), hypertension (55% vs 44%) and diarrhea (23% vs 38%). Conclusions: The primary endpoint was not achieved, but SU tended to be associated with longer mPFS in all cases. In patients with favorable risk, T1 or T2 primary tumors or in those without brain metastasis, significantly longer mPFS were noticed. Brain metastasis was associated with poorer prognosis even if it was stable at baseline. Clinical trial number: NCT01481870. Clinical trial information: 01481870.
Effectiveness and Safety of Sofosbuvir and Ribavirin for Elderly Patients with HCV Genotype 2 Infection
Authors: E. Ogawa, N. Furusyo, H. Nomura, N. Yamashita, K. Dohmen, A. Kawano, K. Takahashi, K. Azuma, T. Satoh, M. Nakamuta, T. Koyanagi, K. Kotoh, S. Shimoda, J. Hayashi
Journal: Journal of Hepatology (2016)
Acute on Chronic Liver Failure Secondary to Drugs: Causes, Outcome and Predictors of Mortality
Authors: H. Devarbhavi, A.K. Choudhury, V.V. Reddy, M.K. Sharma, R. Maiwall, P. Jain, M. Al-Mahtab, Y.K. Chawla, S.S. Tan, Q. Ning, S.S. Hamid, C.E. Eapen, H. Ghazinyan, Z. Duan, A. Sood, G.H. Lee, Z. Abbas, G. Shiha, L.A. Lesmana, D.A. Payawal, G. Kumar, S.K. Sarin
Journal: Journal of Hepatology (2016)
Clinical implications of hepatobiliary scintigraphy and ultrasound in the diagnosis of acute cholecystitis
Authors: Limael E Rodriguez, Luis E Santaliz-Ruiz, Gabriel De La Torre-Bisot, Giovanni Gonzalez, Miguel A Serpa, Felipe Sanchez-Gaetan, Jorge L Martinez-Trabal, Julio A Peguero-Rivera, Guillermo Bolanos-Avila
Journal: International Journal of Surgery (2016)
Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States
Authors: Shreekant V. Parasuraman, Ahmad B. Naim, Dilan C. Paranagama, Maureen Thyne, Sara Goldberger, John O. Mascarenhas, James Mangan, Salman Fazal, Carole B. Miller, Ruben A. Mesa
Journal: Blood (2015)
The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)
Authors: C. Bureau, D. Thabut, R. Layese, V. Bourcier, L. Corvy, V. Petrov-Sanchez, P. Marcellin, D. Guyader, S. Pol, D. Larrey, F. Zoulim, D. Roulot, V. De Ledinghen, D. Ouzan, A. Tran, J.-P. Bronowicki, G. Riachi, P. Cales, J.-M. Peron, L. Alric, M. Bourliere, P. Mathurin, J.-P. Zarski, F. Roudot-Thoraval, P. Nahon
Journal: Journal of Hepatology (2016)
Novel Functional Roles for Ten-Eleven-Translocation 2 (Tet2) in Normal and Leukemic Growth of Mast Cells
Authors: Raghuveer Mali, Holly Rene Martin, Baskar Ramdas, Lakshmi Palam, Valeria Visconte, Tiu Ramon, Helmut Hanenberg, Mingjiang Xu, Reuben Kapur
Journal: Blood (2015)
Hepatitis C Virus Screening Project of Patients on Current Anti-HCV Therapy
Authors: E. Knops, P. Kalaghatgi, M. Neumann-Fraune, E. Heger, E. Schuelter, T. Lengauer, V. Keitel, T. Goeser, N. Schuebel, T. von Hahn, I. Peuser, N. Qurishi, K. Römer, S. Scholten, M. Daeumer, J.S. zur Wiesch, A. Baumgarten, M. Obermeier, H. Walter, R. Kaiser, S. Sierra
Journal: Journal of Hepatology (2016)
HCV Eradication Results in Reduction of Hepatic Venous Pressure Gradient 48 Weeks after End of Treatment; Final Results of the Study of Sofosbuvir plus Ribavirin in Patients with Cirrhosis and Portal Hypertension
Authors: N. Afdhal, T. Asselah, G.T. Everson, J. Bosch, S. De-Oertel, D.M. Brainard, J.G. McHutchison, Y. Yang, K.D. Watt, M. Curry, E. Gane
Journal: Journal of Hepatology (2016)
Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial.
Authors: Robert J. Mayer, Atsushi Ohtsu, Takayuki Yoshino, Alfredo Falcone, Rocio Garcia-Carbonero, Guillem Argiles, Azzurra Damiani, Marc Peeters, Lukas Makris, Alberto Zaniboni, Yasuhiro Shimada, Kentaro Yamazaki, Yoshito Komatsu, Howard S. Hochster, Heinz-Josef Lenz, Ben Tran, Robert Winkler, Paul Bebeau, Mona M. Wahba, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2016)

3547 Background: TAS-102 contains an antineoplastic nucleoside, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a molar ratio of 1:0.5. The efficacy and safety of TAS-102 in patients (pts) with metastatic colorectal cancer refractory/intolerant to standard therapies were confirmed in the RECOURSE trial; enrollment criteria included ≥2 prior lines of standard chemotherapy. Results of RECOURSE showed significant improvement in overall survival (OS) in pts treated with TAS-102 compared with the placebo (pbo) group. Here we report results of RECOURSE in pts classified according to renal and hepatic function. Methods: RECOURSE patients’ kidney and liver functions were classified according to calculated creatinine clearance and National Cancer Institute criteria, respectively. Results: Significant OS benefits for TAS-102 were observed in normal and mild renal and hepatic subgroups compared with pbo (Table). In TAS-102 groups, there were no marked safety differences between pts with normal function and mild renal or hepatic dysfunction. TAS-102 pts with moderate renal impairment had favorable survival benefit, but higher incidence of treatment-related Grade 3 adverse events (AEs) and serious AEs (SAEs), as well as dose reductions compared with pts in other renal subgroups. Conclusions: TAS-102 demonstrated a survival benefit for normal/mild pt subgroups. TAS-102 pts with moderate renal dysfunction had a modest OS benefit with higher frequency of treatment-related AEs. Clinical trial information: NCT01607957. TAS-102 vs Pbo Overall Survival HR (95% CI)* Any TAS-102– Related Grade ≥3 AE n (%) Any TAS-102– Related SAE n (%) All TAS-102 Dose Reductions n (%) Hepatic Normal 0.63 (0.50-0.80) 171/325 (52.6) 25/325 (7.7) 55/325 (16.9) Mild G1 0.71 (0.53-0.95) 71/169 (42) 20/169 (11.8) 16/169 (9.5) Mild G2 0.44 (0.21-0.92) 18/34 (52.9) 5/34 (14.7) 2/34 (5.9) Renal Normal 0.64 (0.51-0.81) 138/306 (45.1) 28/306 (9.2) 33/306 (10.8) Mild 0.71 (0.53-0.96) 94/178 (52.8) 16/178 (9.0) 29/178 (16.3) Moderate 0.85 (0.47-1.56) 29/47 (61.7) 6/47 (12.8) 11/47 (23.4) *Intention-to-treat population; all other data from as-treated population.
Prospective Comparison to Liver Biopsy of Controlled Attenuation Parameter and Proton Density Fat Fraction for Predicting Degree of Steatosis in Non-Alcoholic Fatty Liver Disease
Authors: K. Roberts, A.H. Paredes, C. Lisanti, R. Schwope, K.M. Cebe, J.M.A. Whitehead, J.K. Aden, S.A. Harrison
Journal: Journal of Hepatology (2016)
Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes
Authors: Jeffrey S Painter, Jong Park, Michael J Clemente, Christine L. O'Keefe, Sheng Wei, Jaroslaw P. Maciejewski, Ron Paquette, Thomas P. Loughran, Alan F. List, Pearlie K Epling-Burnette
Journal: Blood (2011)
NUMBER OF PATHOLOGIC NODES IN REGIONS CLOSEST TO THE OESOPHAGUS IS THE STRONGEST PREDICTOR FOR ESOPHAGITIS IN SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMO-RADIATION: AN ANALYSIS OF 170 PATIENTS
Authors: Bart Reymen, Cary Oberije, Judith Van Loon, Angela Van Baardwijk, Rinus Wanders, Esther Troost, Frank Hoebers, Anne-Marie Dingemans, Gerben P Bootsma, Ragnar Lunde, Wiel Geraedts, Dirk De Ruysscher, Philippe Lambin
Journal: Journal of Thoracic Oncology (2013)
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an <i>ALK</i>+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).
Authors: Leena Gandhi, Alice Shaw, Shirish M. Gadgeel, Gregory Riely, Jeremy Cetnar, Howard Jack West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Hassan Zeaiter, Walter Bordogna, Bogdana Balas, Oscar Puig, Volkmar Henschel, Sai-Hong Ignatius Ou
Journal: Journal of Clinical Oncology (2015)

8019 Background: Crizotinib is an approved treatment for patients (pts) with ALK-rearranged (ALK+) NSCLC. However, progression on crizotinib, particularly in the CNS, frequently occurs within a year. Alectinib is a highly selective ALK inhibitor; preclinical data show high CNS exposure and limited efflux. The NP28761 study (NCT01871805) investigated the efficacy/safety of alectinib in ALK+ NSCLC pts in the US and Canada who had progressed on crizotinib. Methods: Pts ≥ 18 yrs with locally advanced/metastatic ALK+ NSCLC (by FDA-approved FISH test) who progressed on crizotinib, with or without prior chemo, were enrolled; alectinib 600mg BID was given until progression, death or withdrawal. The primary endpoint was objective response rate (ORR) by an independent review committee (IRC) based on RECIST v1.1. Secondary endpoints included disease control rate (DCR = ORR plus stable disease); ORR and DCR in the CNS; progression-free survival; CNS progression rate; duration of response; overall survival; safety and quality of life. Results: By 24 Oct 2014, 87 pts were enrolled. Median age 54 yrs; 74% had prior chemo; 55% had baseline CNS mets (21/48 treated). Median follow-up was 21 wks. In the response-evaluable population assessed by IRC (69 pts with baseline measurable disease) ORR was 47.8% (95% CI 35.6–60.2); DCR was 79.7%. In pts with baseline measurable CNS disease (n = 16), IRC CNS ORR was 68.8% (95% CI 41.3–89.0), including 2 CRs; CNS DCR was 100%. When pts with baseline measurable and non-measurable CNS disease were both included (n = 48), CNS DCR was 87.5%, with 9 CNS CRs. 31% of pts had gr3–5 adverse events (AEs), most commonly increased blood CPK (8%), increased ALT (6%) and increased AST (5%); one gr5 AE (hemorrhage) occurred. Low rates of dose interruptions (29%), reductions (14%), and withdrawals (2%) due to AEs were noted. Conclusions: Alectinib was well tolerated and achieved a strong treatment response in ALK+ NSCLC pts who had progressed on crizotinib, with notable CNS activity, a common site of first progression on crizotinib. A global ph3 head-to-head trial of first-line alectinib vs crizotinib and an expanded access program are ongoing. Clinical trial information: NCT01871805.
Adiponectin administration prevents weight gain and glycemic profile changes in diet-induced obese immune deficient Rag1−/− mice lacking mature lymphocytes
Authors: Xiaowen Liu, Nikolaos Perakakis, Huizhi Gong, John P. Chamberland, Mary T. Brinkoetter, Ole-Petter R Hamnvik, Christos S. Mantzoros
Journal: Metabolism (2016)
A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST trial.
Authors: Uwe Platzbecker, Rami S. Komrokji, Pierre Fenaux, Guillermo Garcia-Manero, Ghulam J. Mufti, Mikkael A. Sekeres, Jennie Zhang, Aziz Benzohra, Abderrahmane Laadem, Bond Vo, Kenneth M. Attie, Alan F. List
Journal: Journal of Clinical Oncology (2016)

TPS7076 Background: Management of anemia is a common therapeutic challenge in pts with MDS. Approx. 30% of MDS pts have ≥ 15% RS in the bone marrow (BM) accompanied by ineffective erythropoiesis. Luspatercept (ACE-536), a novel activin type IIB receptor fusion protein, regulates late-stage erythroid differentiation. Preliminary phase 2 data suggest luspatercept improves erythropoiesis in lower-risk MDS pts with promising activity in pts with RS, with achievement of hematologic improvement and reduced need for transfusion in 55% and 39%, respectively, at doses ≥ 0.75 mg/kg. MEDALIST is a phase 3, randomized, double-blind, placebo (PBO)-controlled, multicenter study to determine the efficacy and safety of luspatercept for treatment of anemia in pts with lower-risk MDS ( < 5% BM blasts) and RS ( ≥ 15%) requiring RBC transfusion (average ≥ 2 units packed RBCs/8 weeks [wks]) who are refractory/intolerant or have a low chance of response to erythropoiesis-stimulating agents (serum erythropoietin > 200 IU/L). Methods: Pts aged ≥ 18 years are randomized 2:1 to luspatercept 1.0 mg/kg starting dose or PBO subcutaneously every 3 wks for ≥ 24 wks; no crossover between treatment arms is allowed. Stratification is by baseline RBC transfusion burden ( ≥ 6 RBC units/8 wks vs < 6 RBC units/8 wks) and baseline IPSS-R risk category (Very Low/Low vs Intermediate). Primary endpoint is rate of RBC transfusion independence (RBC-TI) ≥ 8 wks during the first 24 wks of treatment. Secondary endpoints include RBC-TI ≥ 12 wks, safety, quality of life, duration of RBC-TI, AML progression, overall survival, and mean hemoglobin increase ≥ 1.0 g/dL. Pts with evidence of clinical benefit and no progression to IPSS-R High/Very High-risk MDS or AML at wk 25 enter a double-blind extension phase until loss of clinical benefit, unacceptable toxicity, disease progression, or other discontinuation criteria. Post-treatment long-term follow-up is ≥ 2 years. The study is open to enrollment as of Dec 2015; target enrollment is 210 pts. Clinical trial information: NCT02631070.
Baseline HBsAg and HBcrAg Titers Allow Peginterferon Based “Precision Medicine” in Hbeag-Negative Chronic Hepatitis B
Authors: M.M. Peignoux, M. Lapalus, N. Boyer, C. Castelnau, N. Giuily, M. Pouteau, T. Asselah, P. Marcellin
Journal: Journal of Hepatology (2016)
World will lack 18 million health workers by 2030 without adequate investment, warns UN
Authors: Matthew Limb
Journal: BMJ (2016)

A United Nations commission has called for urgent global investment to create new health sector jobs and prevent a projected shortfall of 18 million health workers by 2030.

It said that these health workers will be needed mainly in low and lower middle income countries to meet population needs, achieve universal health coverage, and spur economic growth. Without adequate investment, it warned, “inequalities will rise, and social cohesion will be adversely, even catastrophically, affected.”

The Commission on Health Employment and Economic Growth is chaired by the French president, Francois Hollande, and the South African president, Jacob Zuma. It submitted a report, including 10 recommendations for action, to the UN secretary general, Ban Ki-moon, at …
Failure with DAA Regimens in a High Volume Treatment Center under Real Life Conditions
Authors: J. Petersen, K. Wursthorn, K. Olah, T. Lorenzen, A. Plettenberg, S. Unger, C. Czaja-Harder, K. Matschenz, A. Stoehr, P. Buggisch
Journal: Journal of Hepatology (2016)
Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression
Authors: Meletios Athanasios Dimopoulos, Michel Delforge, Roman Hajek, Martin Kropff, Maria Teresa Petrucci, Philip Lewis, Stefanie Millar, Jingshan Zhang, Jay Mei, Antonio Palumbo
Journal: Blood (2011)
Pregnancy and Successful Delivery in a Patient with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Previously Submitted to Pulmonary Endarterectomy (PEA)
Authors: Chiara Picchi, Marisa Barone, Chiara Beltrametti, Stefano Barco, Diana Irina Iosub, Montanari Laura, Franco Piovella
Journal: Blood (2011)
Excellent Outcome of Risk Stratified Treatment for Childhood Acute Myeloid Leukemia-AML99 Trial. For the Japanese Childhood AML Cooperative Study Group.
Authors: Ichiro Tsukimoto, Akio Tawa, Ryoji Hanada, Ken Tabuchi, Hisato Kigasawa, Shigeru Tsuchiya, Masahiro Tsuchida, Hiromasa Yabe, Hideki Nakayama, Kazuko Kudo, Ryoji Kobayashi, Kazuko Hamamoto, Masue Imaizumi, Akira Morimoto, Keizo Horibe
Journal: Blood (2005)
Treatment of HCV with Simeprevir Associated to Daclatasvir in Patients with Stage 4 and 5 Chronic Renal Failure
Authors: C. Baliellas, P. Marquez-Rodriguez, J. Castellote, T. Casanovas-Taltavull, R. Rota, A. Girbau, E. Dueñas, A. Cachero, X. Xiol
Journal: Journal of Hepatology (2016)
Hepatitis B DNA and Not Quantitative Surface Antigen as a Predictor of Severity of Liver Disease in Untreated Genotype a E-Antigen Negative Disease
Authors: E. Gonsalkorala, M.D. Sadler, M. Bruce, M. Horner, A. Mrzljak, S. Verma, I. Carey, K. Agarwal
Journal: Journal of Hepatology (2016)
CHARACTERIZATION OF SOLITARY PULMONARY LESIONS COMBINING VISUAL PERFUSION AND QUANTITATIVE DIFFUSION MR IMAGING
Authors: Johan Coolen, Frederik De Keyzer, Herbert Decaluwé, Walter De Wever, Johan Vansteenkiste, Christophe Dooms, Erik Verbeken, Paul De Leyn, Dirk Van Raemdonck, Steven Dymarkowski, Kristiaan Nackaerts, Johny Verschakelen
Journal: Journal of Thoracic Oncology (2013)
Integrated Analysis of SOF + RBV or LDV/SOF for the Treatment of Genotype 4 Chronic HCV Infection
Authors: G.E. Esmat, G. Shiha, A. Abergel, T. Asselah, A. Kohli, S. Kottilil, P.J. Ruane, S. Naggie, W.H. Doss, T.A. Hahambis, C. Letterio, M. Natha, B. Kreter, K. Kersey, D. Brainard, S.J. Knox
Journal: Journal of Hepatology (2016)
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Authors: Joo Young Kim, Jacqueline A. Brosnan-Cashman, Soyeon An, Sung Joo Kim, Ki-Byung Song, Min-Sun Kim, Mi-Ju Kim, Dae Wook Hwang, Alan K. Meeker, Eunsil Yu, Song Cheol Kim, Ralph H. Hruban, Christopher M. Heaphy, Seung-Mo Hong
Journal: Clinical Cancer Research (2016)

Purpose: Alternative lengthening of telomeres (ALT), a telomerase-independent telomere maintenance mechanism, is strongly associated with ATRX and DAXX alterations and occurs frequently in pancreatic neuroendocrine tumors (PanNET).Experimental Design: In a Korean cohort of 269 surgically resected primary PanNETs and 19 sporadic microadenomas, ALT status and nuclear ATRX and DAXX protein expression were assessed and compared with clinicopathologic factors.Results: In PanNETs, ALT or loss of ATRX/DAXX nuclear expression was observed in 20.8% and 19.3%, respectively, whereas microadenomas were not altered. ALT-positive PanNETs displayed a significantly higher grade, size, and pT classification (all, P < 0.001). ALT also strongly correlated with lymphovascular (P < 0.001) and perineural invasion (P = 0.001) and the presence of lymph node (P < 0.001) and distant metastases (P = 0.002). Furthermore, patients with ALT-positive primary PanNETs had a shorter recurrence-free survival [HR = 3.38; 95% confidence interval (CI), 1.83-6.27; P < 0.001]. Interestingly, when limiting to patients with distant metastases, those with ALT-positive primary tumors had significantly better overall survival (HR = 0.23; 95% CI, 0.08-0.68; P = 0.008). Similarly, tumors with loss of ATRX/DAXX expression were significantly associated with ALT (P < 0.001), aggressive clinical behavior, and reduced recurrence-free survival (P < 0.001). However, similar to ALT, when limiting to patients with distant metastases, loss of ATRX/DAXX expression was associated with better overall survival (P = 0.003).Conclusions: Both primary ALT-positive and ATRX/DAXX-negative PanNETs are independently associated with aggressive clinicopathologic behavior and displayed reduced recurrence-free survival. In contrast, ALT activation and loss of ATRX/DAXX are both associated with better overall survival in patients with metastases. Therefore, these biomarkers may be used as prognostic markers depending on the context of the disease. Clin Cancer Res; 23(6); 1598-606. ©2016 AACR.
P0984 : Development and validation of a simple clinical prediction model to identify patients with nonalcoholic steatohepatitis resolution after 52 weeks of lifestyle modification
Authors: E. Vilar-Gomez, A. Yasells Garcia, L. Calzadilla Bertot, Y. Martínez Perez, M. Romero-Gomez, M. Diago
Journal: Journal of Hepatology (2015)
P0689 : The hepatitis C virus contributes to the aggravation of the immunosuppressive environment by increasing the suppressive activity of natural regulatory T cells
Authors: L. Ouaguia, O. Morales, C. Wychowski, A. Carpentier, L. Aoudjehane, J. Dubuisson, Y. Calmus, Y. deLaunoit, F. Conti, N. Delhem
Journal: Journal of Hepatology (2015)